NCG-B2m-KO Mouse Details

NCG-B2m-KO is a triple-immunodeficient NCG mouse with a B2m gene knockout. B2M (also known as Ly-m11, beta2m, beta2-m, β2-microglobulin) is a component of the MHC complex essential for MHC I expression. NCG-B2m-KO mice express low levels of MHC I on cell membranes and are resistant to graft versus host disease (GvHD).

Origin

The NCG mouse strain was co-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014 and transferred to CRL in 2016. Nanjing Galaxy Biopharma became Gempharmatech in 2019, while retaining oversight of the original NCG colony. GPT later modified the original NCG strain by knocking out the B2M gene creating the NCG-B2m-KO. The strain was transferred to Charles River in 2022.

Coat Color

White

Strain Code

721

Ideal For

Oncology, immunology, infectious disease, graft vs. host disease, diabetes, regenerative medicine, human organ transplantation and PBMC NCG model

growth chart

LOCATION: Wilmington
UNIT: W08
Download the Report

➤ DOWNLOAD OUR CATALOG for instant access to Standard List Pricing

➤ TALK TO US to discuss organization or volume-based discounts

Try out this model with our animal evaluation program

Poster

Delayed Onset of GvHD in PBMC Humanized NCG-B2m-KO Mice Provides an Enhanced Model for Oncology Studies

Immunodeficient Model Selection Poster
Compare immune cell deficits (T/B/NK), engraftment applications, and practical study considerations (e.g., leakiness and radiation tolerance) side-by-side across multiple immunodeficient mouse and rat models. Download Poster

WEBINAR
Advance Your Oncology and Immunology Research with Next-Generation Mouse Models
Learn how NCG immunodeficient and humanized mouse models advance oncology and immunology research, accelerating predictive humanized and PDX applications. Watch on Demand